| 1* |
Development_Flt3 signaling |
0.0007298 |
6/41 |
| 2* |
Mechanisms of CFTR activation by S-nitrosoglutathione (normal and CF) |
0.001463 |
4/19 |
| 3 |
Apoptosis and survival_BAD phosphorylation |
0.00261 |
5/36 |
| 4* |
Development_A2A receptor signaling |
0.00261 |
5/36 |
| 5* |
dATP/dITP metabolism |
0.003148 |
6/54 |
| 6* |
Apoptosis and survival_Anti-apoptotic action of membrane-bound ESR1 |
0.003612 |
4/24 |
| 7* |
Development_SSTR2 in regulation of cell proliferation |
0.004211 |
4/25 |
| 8* |
Development_IGF-1 receptor signaling |
0.006329 |
5/44 |
| 9* |
Development_EGFR signaling via small GTPases |
0.007273 |
4/29 |
| 10* |
Development_GM-CSF signaling |
0.008383 |
5/47 |
| 11* |
Translation _Regulation activity of EIF4F |
0.009983 |
5/49 |
| 12 |
Cell cycle_Spindle assembly and chromosome separation |
0.01035 |
4/32 |
| 13* |
Development_PDGF signaling via MAPK cascades |
0.0128 |
4/34 |
| 14 |
Development_VEGF signaling and activation |
0.0128 |
4/34 |
| 15* |
Immune response_IL-4 signaling pathway |
0.01416 |
4/35 |
| 16* |
Cytoskeleton remodeling_Role of PDGFs in cell migration |
0.01821 |
3/21 |
| 17 |
Aspartate and asparagine metabolism |
0.01821 |
3/21 |
| 18* |
TTP metabolism |
0.01876 |
4/38 |
| 19* |
Development_A1 receptor signaling |
0.01876 |
4/38 |
| 20* |
dGTP metabolism |
0.01876 |
4/38 |
| 21* |
Transcription_P53 signaling pathway |
0.02047 |
4/39 |
| 22 |
Signal transduction_AKT signaling |
0.02047 |
4/39 |
| 23* |
Aminoacyl-tRNA biosynthesis in cytoplasm/Rodent version |
0.02067 |
3/22 |
| 24* |
Oxidative stress_Role of ASK1 under oxidative stress |
0.02067 |
3/22 |
| 25* |
Aminoacyl-tRNA biosynthesis in cytoplasm |
0.02067 |
3/22 |
| 26* |
Development_GDNF family signaling |
0.02228 |
4/40 |
| 27* |
Immune response_CD28 signaling |
0.02619 |
4/42 |
| 28 |
Development_FGFR signaling pathway |
0.02829 |
4/43 |
| 29* |
Immune response_TREM1 signaling pathway |
0.03278 |
4/45 |
| 30* |
Cholesterol and Sphingolipids transport/Influx to the early endosome in lung |
0.03432 |
2/11 |
| 31* |
Immune response_IL-2 activation and signaling pathway |
0.03517 |
4/46 |
| 32* |
dCTP/dUTP metabolism |
0.03517 |
4/46 |
| 33* |
Regulation of lipid metabolism_Insulin regulation of fatty acid methabolism |
0.03517 |
4/46 |
| 34* |
Immune response_IL-4 - antiapoptotic action |
0.03561 |
3/27 |
| 35* |
Some pathways of EMT in cancer cells |
0.04025 |
4/48 |
| 36* |
Phospholipid metabolism p.1 |
0.04047 |
2/12 |
| 37* |
Immune response_PIP3 signaling in B lymphocytes |
0.04279 |
3/29 |
| 38* |
Apoptosis and survival_p53-dependent apoptosis |
0.04279 |
3/29 |
| 39* |
Development_VEGF signaling via VEGFR2 - generic cascades |
0.04279 |
3/29 |
| 40* |
Development_PDGF signaling via STATs and NF-kB |
0.04279 |
3/29 |
| 41* |
Cytoskeleton remodeling_Cytoskeleton remodeling |
0.04526 |
6/96 |
| 42* |
Development_CNTF receptor signaling |
0.04663 |
3/30 |
| 43* |
Keratan sulfate metabolism p.1 |
0.047 |
2/13 |
|
Pathway #
|
Pathway Name
|
P-Value
|
# Genes
|
|
Pathways of Genes Uniquely Regulated by Combination+Estrogen+20 nM Endoxifen
|
| 1* |
Immune response_CD40 signaling |
0.002114 |
5/54 |
| 2 |
Apoptosis and survival_BAD phosphorylation |
0.003086 |
4/36 |
| 3 |
G-protein signaling_Proinsulin C-peptide signaling |
0.003769 |
4/38 |
| 4 |
Development_FGFR signaling pathway |
0.005909 |
4/43 |
| 5* |
Development_Glucocorticoid receptor signaling |
0.006685 |
3/23 |
| 6* |
DNA damage_ATM/ATR regulation of G2/M checkpoint |
0.009461 |
3/26 |
| 7* |
DNA damage_DNA-damage-induced responses |
0.009651 |
2/9 |
| 8* |
Cell cycle_Role of SCF complex in cell cycle regulation |
0.01282 |
3/29 |
| 9 |
Development_EGFR signaling via small GTPases |
0.01282 |
3/29 |
| 10* |
Apoptosis and survival_Role of IAP-proteins in apoptosis |
0.01282 |
3/29 |
| 11* |
DNA damage_Brca1 as a transcription regulator |
0.01407 |
3/30 |
| 12* |
G-protein signaling_G-Protein alpha-12 signaling pathway |
0.01678 |
3/32 |
| 13* |
Cell cycle_Role of APC in cell cycle regulation |
0.01678 |
3/32 |
| 14* |
Histidine-glutamate-glutamine metabolism |
0.01823 |
3/33 |
| 15* |
Apoptosis and survival_Ceramides signaling pathway |
0.01975 |
3/34 |
| 16* |
Apoptosis and survival_DNA-damage-induced apoptosis |
0.02634 |
2/15 |
| 17 |
Signal transduction_AKT signaling |
0.0284 |
3/39 |
| 18* |
Development_Thrombopoietin-regulated cell processes |
0.0344 |
3/42 |
| 19* |
Blood coagulation_GPVI-dependent platelet activation |
0.03654 |
3/43 |
| 20* |
Development_TGF-beta-dependent induction of EMT via RhoA, PI3K and ILK. |
0.03654 |
3/43 |
| 21 |
Transport_RAN regulation pathway |
0.03714 |
2/18 |
| 22* |
Development_FGF2-dependent induction of EMT |
0.03714 |
2/18 |
| 23* |
Histidine-glutamate-glutamine and proline metabolism/Rodent version |
0.04101 |
3/45 |
| 24* |
Development_EGFR signaling via PIP3 |
0.04106 |
2/19 |
| 25* |
Gamma-aminobutyrate (GABA) biosynthesis and metabolism |
0.04513 |
2/20 |
| 26 |
Aspartate and asparagine metabolism |
0.04934 |
2/21 |
|
Pathway #
|
Pathway Name
|
P-Value
|
# Genes
|
|
Pathways of Genes Commonly Regulated by Combination+Estrogen+both 100 and 20 nM Endoxifen
|
| 1 |
Development_EDG3 signaling pathway |
3.144E−06 |
8/26 |
| 2 |
Muscle contraction_Regulation of eNOS activity in endothelial cells |
7.175E−06 |
10/47 |
| 3 |
Muscle contraction_EDG5-mediated smooth muscle contraction |
1.047E−05 |
7/22 |
| 4 |
Neurophysiological process_ACM regulation of nerve impulse |
2.819E−05 |
8/34 |
| 5 |
Muscle contraction_ACM regulation of smooth muscle contraction |
3.538E−05 |
8/35 |
| 6 |
Cytoskeleton remodeling_ACM3 and ACM4 in keratinocyte migration |
9.185E−05 |
6/21 |
| 7 |
Development_Activation of astroglial cells proliferation by ACM3 |
9.185E−05 |
6/21 |
| 8 |
Transport_ACM3 in salivary glands |
0.0002642 |
6/25 |
| 9 |
Cell cycle_Role of Nek in cell cycle regulation |
0.0006248 |
6/29 |
| 10 |
Cell cycle_Chromosome condensation in prometaphase |
0.0007215 |
5/20 |
| 11 |
Signal transduction_Erk Interactions: Inhibition of Erk |
0.0007568 |
6/30 |
| 12 |
Muscle contraction_ GPCRs in the regulation of smooth muscle tone |
0.0008466 |
8/54 |
| 13 |
Cell cycle_Spindle assembly and chromosome separation |
0.001085 |
6/32 |
| 14 |
Transcription_ChREBP regulation pathway |
0.001093 |
4/13 |
| 15 |
Development_G-Proteins mediated regulation MARK-ERK signaling |
0.001768 |
6/35 |
| 16 |
Cytoskeleton remodeling_ESR1 action on cytoskeleton remodeling |
0.001965 |
4/15 |
| 17 |
Apoptosis and survival_Beta-2 adrenergic receptor anti-apoptotic action |
0.001965 |
4/15 |
| 18 |
Cell cycle_The metaphase checkpoint |
0.002057 |
6/36 |
| 19 |
G-protein signaling_Proinsulin C-peptide signaling |
0.002738 |
6/38 |
| 20 |
Development_EDG1 signaling pathway |
0.00303 |
5/27 |
| 21 |
Development_Alpha-2 adrenergic receptor activation of ERK |
0.003576 |
6/40 |
| 22 |
Transport_RAN regulation pathway |
0.004031 |
4/18 |
| 23 |
Regulation of lipid metabolism_Regulation of lipid metabolism |
0.004193 |
5/29 |
| 24 |
Neurophysiological process_NMDA-dependent postsynaptic potentiation |
0.004812 |
7/56 |
| 25 |
Neurophysiological process_Glutamate regulation of Dopamine D1A receptor |
0.005644 |
5/31 |
| 26 |
Cytoskeleton remodeling_Role of PKA in cytoskeleton reorganisation |
0.005644 |
5/31 |
| 27 |
Signal transduction_Activation of PKC via G-Protein coupled receptor |
0.005805 |
6/44 |
| 28 |
Signal transduction_Calcium signaling |
0.006488 |
5/32 |
| 29 |
Cell cycle_Sister chromatid cohesion |
0.007215 |
4/21 |
| 30 |
G-protein signaling_EDG5 signaling |
0.007215 |
4/21 |
| 31 |
Development_Role of HDAC and CaMK in control of skeletal myogenesis |
0.008043 |
6/47 |
| 32 |
Signal transduction_cAMP signaling |
0.008435 |
5/34 |
| 33 |
Immune response_Alternative complement pathway |
0.008435 |
5/34 |
| 34 |
Development_VEGF signaling and activation |
0.008435 |
5/34 |
| 35 |
Regulation of lipid metabolism_Stimulation of Arachidonic acid production |
0.008911 |
6/48 |
| 36 |
Cytoskeleton remodeling_Alpha-1A adrenergic receptor inhibition of PI3K |
0.00917 |
3/12 |
| 37 |
Transport_RAB1A regulation pathway |
0.00917 |
3/12 |
| 38 |
Transcription_Receptor-mediated HIF regulation |
0.009546 |
5/35 |
| 39 |
Development_Endothelin-1/EDNRA transactivation of EGFR |
0.009546 |
5/35 |
| 40 |
Oxidative stress_Angiotensin II-induced production of ROS |
0.01006 |
4/23 |
| 41 |
Apoptosis and survival_BAD phosphorylation |
0.01075 |
5/36 |
| 42 |
Translation _Regulation of translation initiation |
0.01173 |
4/24 |
| 43 |
Cardiac Hypertrophy_Ca(2+)-dependent NF-AT signaling |
0.01206 |
5/37 |
| 44 |
Transcription_CREB pathway |
0.01206 |
5/37 |
| 45 |
Cell adhesion_Histamine H1 receptor signaling |
0.01206 |
5/37 |
| 46 |
Translation_Insulin regulation of translation |
0.01348 |
5/38 |
| 47 |
Neurophysiological process_Dopamine D2 receptor signaling in CNS |
0.01356 |
4/25 |
| 48 |
Development_Angiotensin activation of Akt |
0.01356 |
4/25 |
| 49 |
Blood coagulation_GPCRs in platelet aggregation |
0.01428 |
6/53 |
| 50 |
Development_EDG6 signaling pathway |
0.01435 |
3/14 |
